Mechanistically, NR5A2 and NCOA3 cooperate to upregulate NRF2, a transcription factor regulating antioxidant gene expression, and inhibiting NR5A2 or NCOA3 enhances BETi’s anti-cancer effects both in vitro and in vivo. Here, NR5A2 is linked to cancer.